Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus apatinib as first-line treatment for advanced squamous non-small cell lung cancer
ChiCTR1800019329Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in Pulmonary squamous cell carcinoma, sponsored by Chinese PLA General Hospital. Primary endpoint: progression-free survival. Started Oct 2018; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1800019329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019329.